Market Snapshot

BSE Sensex: 83576.24 -0.72%
BSE 500: 36807.62 -0.89%
BSE 200: 11620.53 -0.79%
BSE 100: 26904.82 -0.73%
BSE MidCap: 46304.8 -0.90%
BSE SmallCap: 49912.11 -1.74%
BSE BANKEX: 66616.92 -0.58%
BSE IT: 36795.24 0.03%
Nifty 50: 25683.3 -0.75%
Nifty 500: 23467.35 -0.90%
Nifty 200: 14306.95 -0.79%
Nifty 100: 26252.95 -0.79%
Nifty Midcap 100: 59748.15 -0.79%
Nifty Small 100: 17282.65 -1.81%
Nifty IT: 38027.2 0.28%
Nifty PSU Bank: 8601.05 0.18%

News:

Protean eGov Technologies bags...
PTC Industries? arm secures ma...
Globus Spirits reports multi-f...
IREDA Q3 PAT jumps 15% YoY to ...
Tejas Networks reports dismal ...

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

09 Jan 2026 | 03:59 PM

173.95

-4.80 (-2.69%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-33.15%

Return (1Y)

Underperformed BSE Healthcare by 30.7%
More Volatile

2.76%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.8%
Inconsistent Performer

3/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

284

162

News & Announcements

Marksans Pharma to announce Quarterly Result
2 days ago

Marksans Pharma to announce Quarterly Result

10 - Jan - 2026 12:00 | 2 days ago

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 5 February 2026.
Powered by Capital Market - Live News
Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution
53 days ago

Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution

20 - Nov - 2025 12:00 | 53 days ago

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution from UK MHRA.
Powered by Capital Market - Live News
Marksans Pharma?s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
54 days ago

Marksans Pharma?s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets

19 - Nov - 2025 12:00 | 54 days ago

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).
Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma?s portfolio in the US generic pharmaceutical market.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
The company?s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.
Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.
Powered by Capital Market - Live News
Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets
54 days ago

Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets

19 - Nov - 2025 12:00 | 54 days ago

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860.

Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Marksans Pharma Ltd has decreased by -26.31% since past 3 Months
MF shareholding in Marksans Pharma Ltd has increased by 10.53% since past 3 Months
FII shareholding in Marksans Pharma Ltd has decreased by -20.4% since past 1 Year
MF shareholding in Marksans Pharma Ltd has increased by 29.63% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

General Notifications

My Notifications

Research Notifications

Marksans Pharma Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

173.95 -4.80 (-2.69%)

News & Announcements

Price vs Volume

Stock Trivia

Marksans Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

173.95

-4.80 (-2.69%)